141,479 research outputs found
Recommended from our members
canEvolve: A Web Portal for Integrative Oncogenomics
Background & objective: Genome-wide profiles of tumors obtained using functional genomics platforms are being deposited to the public repositories at an astronomical scale, as a result of focused efforts by individual laboratories and large projects such as the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium. Consequently, there is an urgent need for reliable tools that integrate and interpret these data in light of current knowledge and disseminate results to biomedical researchers in a user-friendly manner. We have built the canEvolve web portal to meet this need. Results: canEvolve query functionalities are designed to fulfill most frequent analysis needs of cancer researchers with a view to generate novel hypotheses. canEvolve stores gene, microRNA (miRNA) and protein expression profiles, copy number alterations for multiple cancer types, and protein-protein interaction information. canEvolve allows querying of results of primary analysis, integrative analysis and network analysis of oncogenomics data. The querying for primary analysis includes differential gene and miRNA expression as well as changes in gene copy number measured with SNP microarrays. canEvolve provides results of integrative analysis of gene expression profiles with copy number alterations and with miRNA profiles as well as generalized integrative analysis using gene set enrichment analysis. The network analysis capability includes storage and visualization of gene co-expression, inferred gene regulatory networks and protein-protein interaction information. Finally, canEvolve provides correlations between gene expression and clinical outcomes in terms of univariate survival analysis. Conclusion: At present canEvolve provides different types of information extracted from 90 cancer genomics studies comprising of more than 10,000 patients. The presence of multiple data types, novel integrative analysis for identifying regulators of oncogenesis, network analysis and ability to query gene lists/pathways are distinctive features of canEvolve. canEvolve will facilitate integrative and meta-analysis of oncogenomics datasets
SIGMA: A System for Integrative Genomic Microarray Analysis of Cancer Genomes
BACKGROUND: The prevalence of high resolution profiling of genomes has created a need for the integrative analysis of information generated from multiple methodologies and platforms. Although the majority of data in the public domain are gene expression profiles, and expression analysis software are available, the increase of array CGH studies has enabled integration of high throughput genomic and gene expression datasets. However, tools for direct mining and analysis of array CGH data are limited. Hence, there is a great need for analytical and display software tailored to cross platform integrative analysis of cancer genomes. RESULTS: We have created a user-friendly java application to facilitate sophisticated visualization and analysis such as cross-tumor and cross-platform comparisons. To demonstrate the utility of this software, we assembled array CGH data representing Affymetrix SNP chip, Stanford cDNA arrays and whole genome tiling path array platforms for cross comparison. This cancer genome database contains 267 profiles from commonly used cancer cell lines representing 14 different tissue types. CONCLUSION: In this study we have developed an application for the visualization and analysis of data from high resolution array CGH platforms that can be adapted for analysis of multiple types of high throughput genomic datasets. Furthermore, we invite researchers using array CGH technology to deposit both their raw and processed data, as this will be a continually expanding database of cancer genomes. This publicly available resource, the System for Integrative Genomic Microarray Analysis (SIGMA) of cancer genomes, can be accessed at
Computational study of cancer
In my thesis, I focused on integrative analysis of high-throughput oncogenomic data. This was done in two parts: In the first part, I describe IntOGen, an integrative data mining tool for the study of cancer. This system collates, annotates, pre-processes and analyzes large-scale data for transcriptomic, copy number aberration and mutational profiling of a large number of tumors in multiple cancer types. All oncogenomic data is annotated with ICD-O terms. We perform analysis at different levels of complexity: at the level of genes, at the level of modules, at the level of studies and finally combination of studies. The results are publicly available in a web service. I also present the Biomart interface of IntOGen for bulk download of data. In the final part, I propose a methodology based on sample-level enrichment analysis to identify patient subgroups from high-throughput profiling of tumors. I also apply this approach to a specific biological problem and characterize properties of worse prognosis tumor in multiple cancer types. This methodology can be used in the translational version of IntOGen
The Effect of Exercise on Cancer-related Fatigue in Women Receiving Treatment for Non-metastatic Breast Cancer: Evidence-based Practice Literature Review
The purpose of this integrative literature review is to determine if an exercise program has an effect on reducing cancer-related fatigue in women receiving treatment for non-metastatic breast cancer. Key words used in the database search parameters of nursing (CINAHL) and medical (PubMed) literature (published 2002 to 2012) included “breast cancer,” “exercise,” and “fatigue.” Data analysis and findings of the studies demonstrated that both supervised and home-based exercise programs are safe and effective in reducing cancer-related fatigue in the non-metastatic breast cancer patient population. However, additional studies need to be completed before definitive conclusions can be made, especially in regards to the specific type, duration, and intensity of exercise prescription needed for each patient. Findings of these studies can be applied to the clinical practice of an advanced practice registered nurse by providing evidence on the importance of screening for and providing recommendations to treat cancer-related fatigue in women treated for non-metastatic breast cancer
Understanding genomic alterations in cancer genomes using an integrative network approach
In recent years, cancer genome sequencing and other high-throughput studies
of cancer genomes have generated many notable discoveries. In this review,
Novel genomic alteration mechanisms, such as chromothripsis (chromosomal
crisis) and kataegis (mutation storms), and their implications for cancer are
discussed. Genomic alterations spur cancer genome evolution. Thus, the
relationship between cancer clonal evolution and cancer stems cells is
commented. The key question in cancer biology concerns how these genomic
alterations support cancer development and metastasis in the context of
biological functioning. Thus far, efforts such as pathway analysis have
improved the understanding of the functional contributions of genetic mutations
and DNA copy number variations to cancer development, progression and
metastasis. However, the known pathways correspond to a small fraction,
plausibly 5-10%, of somatic mutations and genes with an altered copy number. To
develop a comprehensive understanding of the function of these genomic
alterations in cancer, an integrative network framework is proposed and
discussed. Finally, the challenges and the directions of studying cancer omic
data using an integrative network approach are commented.Comment: 2 figs, more related papers at http://www.cancer-systemsbiology.org.
appears in Cancer Letter, 201
OPTIMIZED CROSS-STUDY ANALYSIS OF MICROARRAY-BASED PREDICTORS
Background: Microarray-based gene expression analysis is widely used in cancer research to discover molecular signatures for cancer classification and prediction. In addition to numerous independent profiling projects, a number of investigators have analyzed multiple published data sets for purposes of cross-study validation. However, the diverse microarray platforms and technical approaches make direct comparisons across studies difficult, and without means to identify aberrant data patterns, less than optimal. To address this issue, we previously developed an integrative correlation approach to systematically address agreement of gene expression measurements across studies, providing a basis for cross-study validation analysis. Here we generalize this methodology to provide a metric for evaluating the overall efficacy of preprocessing and cross-referencing, and explore optimal combinations of filtering and cross-referencing strategies. We operate in the context of validating prognostic breast cancer gene expression signatures on data reported by three different groups, each using a different platform.
Results: To evaluate overall cross-platform reproducibility in the context of a specific prediction problem, we suggest integrative association, that is the cross-study correlation of gene-specific measure of association with the phenotype predicted. Specifically, in this paper we use the correlation among the Cox proportional hazard coefficients for association of gene expression to relapse free survival (RFS). Gene filtering by integrative correlation to select reproducible genes emerged as the key factor to increase the integrative association, while alternative methods of gene cross-referencing and gene filtering proved only to modestly improve the overall reproducibility. Patient selection was another major factor affecting the validation process. In particular, in one of the studies considered, gene expression association with RFS varied across subsets of patients that differ by their ascertainment criteria. One of the subsets proved to be highly consistent with other studies, while others showed significantly lower consistency. Third, as expected, use of cluster-specific mean expression profiles in the Cox model yielded more generalizable results than expression data from individual genes. Finally, by using our approach we were able to validate the association between the breast cancer molecular classes proposed by Sorlie et al. and RFS.
Conclusions: This paper provides a simple, practical and comprehensive technique for measuring consistency of molecular classification results across microarray platforms, without requiring subjective judgments about membership of samples in putative clusters. This methodology will be of value in consistently typing breast and other cancers across different studies and platforms in the future. Although the tumor subtypes considered here have been previously validated by their proponents, this is the first independent validation, and the first to include the Affymetrix platform
Integrative Analysis of Gene Expression Data Including an Assessment of Pathway Enrichment for Predicting Prostate Cancer
Background: Microarray technology has been previously used to identify genes that are differentially expressed between tumour and normal samples in a single study, as well as in syntheses involving multiple studies. When integrating results from several Affymetrix microarray datasets, previous studies summarized probeset-level data, which may potentially lead to a loss of information available at the probe-level. In this paper, we present an approach for integrating results across studies while taking probe-level data into account. Additionally, we follow a new direction in the analysis of microarray expression data, namely to focus on the variation of expression phenotypes in predefined gene sets, such as pathways. This targeted approach can be helpful for revealing information that is not easily visible from the changes in the individual genes. Results: We used a recently developed method to integrate Affymetrix expression data across studies. The idea is based on a probe-level based test statistic developed for testing for differentially expressed genes in individual studies. We incorporated this test statistic into a classic random-effects model for integrating data across studies. Subsequently, we used a gene set enrichment test to evaluate the significance of enriched biological pathways in the differentially expressed genes identified from the integrative analysis. We compared statistical and biological significance of the prognostic gene expression signatures and pathways identified in the probe-level model (PLM) with those in the probeset-level model (PSLM). Our integrative analysis of Affymetrix microarray data from 110 prostate cancer samples obtained from three studies reveals thousands of genes significantly correlated with tumour cell differentiation. The bioinformatics analysis, mapping these genes to the publicly available KEGG database, reveals evidence that tumour cell differentiation is significantly associated with many biological pathways. In particular, we observed that by integrating information from the insulin signalling pathway into our prediction model, we achieved better prediction of prostate cancer. Conclusions: Our data integration methodology provides an efficient way to identify biologically sound and statistically significant pathways from gene expression data. The significant gene expression phenotypes identified in our study have the potential to characterize complex genetic alterations in prostate cancer
- …